Indivior Pharmaceuticals (INDV) Return on Assets (2025 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Return on Assets of 0.0% for Q1 2026, little changed year-over-year from 0.0% in Q1 2025, and up 30.44% quarter-over-quarter from 0.0% in Q4 2025.
Indivior Pharmaceuticals (INDV) Return on Assets (2025 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Return on Assets history runs 2 years deep, the most recent figure standing at 0.0% for Q1 2026.
- In Q1 2026, Return on Assets changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
- Return on Assets for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
- The five-year high for Return on Assets was 0.0% in Q1 2026, with the low at 0.0% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 0.00% |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 0.00% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 0.00% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 0.00% |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 0.00% |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 0.00% |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 0.00% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 0.00% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 0.00% |
| 10 | Indivior Pharmaceuticals | 4.53 Bn | 4.31 Bn | 294.00 Mn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00% |
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |